The 2025 annual conference of the American Society of Clinical Oncology (ASCO) is being held in the USA, with the participation of over 40,000 specialists from around the world. This is one of the key events in the field, where scientists, doctors, and industry representatives come together to discuss the latest advances in cancer treatment and patient care.
At the poster session, Ilya Pokataev, Head of the Clinical Research Center, Head of the Chemotherapeutic Treatment Service, MD, Doctor of the highest category at the Cancer Center No. 1 of the S.S. Yudin State Clinical Hospital, presented the results of a phase III clinical trial of the biosimilar pembrolizumab (TN Arfleida®), developed by the R-Pharm group.
The trial involved more than 250 patients with skin melanoma randomly divided into two groups. One group received the original pembrolizumab, the other received the drug Arfleida. The results demonstrated that the drug from the R-Pharm group is just as effective and safe as the original medication.
“There should be no barriers to scientific and medical knowledge as only wide awareness of the medical community will make it possible to provide modern therapy to patients all over the world. A report on a drug developed by a Russian pharmaceutical company showcased at a conference in the USA can be regarded as a major breakthrough. This reflects the international recognition of domestic pharmaceuticals and the willingness of foreign experts to engage in constructive dialogue,” says Mikhail Samsonov, Chief Medical Officer of the R-Pharm Group.
